<DOC>
	<DOC>NCT01247883</DOC>
	<brief_summary>This study investigates the safety, tolerability and pharmacokinetics of PF-04634817 when respectively given orally as a single tablet dose and a single dose of a solution.</brief_summary>
	<brief_title>A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male and/or female subjects (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history and full physical examination.) Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease; Treatment with an investigational drug within 30 days or 5 halflives (whichever is longer) preceding the first dose of study medication; Use of tobacco or nicotinecontaining products in excess of the equivalent of 5 cigarettes per day; Nursing females; Females of childbearing potential.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>healthy volunteers</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>solution</keyword>
	<keyword>tablet</keyword>
</DOC>